Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
July 27 2021 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company
developing innovative therapeutics to treat life-threatening
diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief
Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
Chief Medical Officer of Aravive, will participate in a virtual
fireside chat at the 2021 BTIG Biotechnology Conference on August
9, 2021, at 9:30 AM ET. Aravive will also be participating in
one-on-one meetings at the conference.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative if you have interest.
About AraviveAravive, Inc. is a
clinical-stage oncology company developing innovative therapeutics
to treat life-threatening diseases. Aravive’s lead therapeutic,
AVB-500, is a first-in-class ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor cell
growth, tumor metastasis, resistance to treatment and decreased
survival. AVB-500 has the potential to be combined with multiple
anti-cancer therapies across several tumor types, due to its novel
mechanism of action and favorable safety profile. AVB-500 has been
granted Fast Track Designation by the U.S. Food and Drug
Administration in platinum resistant recurrent ovarian cancer. The
Company is currently evaluating AVB-500 in a registrational Phase 3
trial in platinum resistant ovarian cancer and a Phase 1b/2 trial
in clear cell renal cell carcinoma. Aravive plans to initiate a
Phase 1b/2 trial evaluating AVB-500 in first-line treatment of
pancreatic cancer in the second half of 2021. The Company is based
in Houston, Texas and received a Product Development Award from the
Cancer Prevention & Research Institute of Texas (CPRIT) in
2016. For more information, please visit www.aravive.com.
Contact:Joseph T. SchepersVP, Investor
Relations, Aravive, Inc.jschepers@aravive.com (770) 558-5517
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024